GlassScriptPhysician profile
Mollie R Deshazo
NPI 1487603841
$37,277.75
in general payments reported to CMS, 2019-2025
31 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $167 · 2021: $64.99 · 2022: $1,212 · 2023: $21K · 2024: $15K · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Consulting Fee: $10K · Travel and Lodging: $3,709 · Food and Beverage: $2,711 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,777.50 |
| Consulting Fee | $10,235.75 |
| Travel and Lodging | $3,708.72 |
| Food and Beverage | $2,710.72 |
| Education | $230.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $11,038.88 | 2022-2023 | Padcev |
| Janssen Scientific Affairs, LLC | $10,235.75 | 2023-2024 | Erleada |
| Pfizer INC. | $6,954.01 | 2022-2024 | |
| Astellas Pharma US INC | $6,156.46 | 2022-2024 | Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $402.07 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $365.28 | 2022-2025 | Lynparza, Imfinzi |
| Dendreon Pharmaceuticals LLC | $346.97 | 2022-2024 | Provenge |
| Exelixis INC. | $219.72 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $191.78 | 2019-2024 | Opdivo, Krazati |
| Eisai INC. | $175.88 | 2022-2024 | |
| Janssen Biotech, INC. | $167.77 | 2022-2024 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $148.26 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $131.92 | 2022-2025 | |
| Advanced Accelerator Applications | $124.24 | 2019 | |
| Sun Pharmaceutical Industries INC. | $93.27 | 2022-2023 | Yonsa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $77.58 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $64.99 | 2021 | |
| Sumitomo Pharma America, INC. | $53.71 | 2023-2024 | Orgovyx |
| Tempus Ai, INC | $47.90 | 2024 | |
| Genzyme Corporation | $47.82 | 2022 | |
| Aveo Pharmaceuticals, INC. | $37.47 | 2022 | |
| Myovant Sciences INC. | $35.74 | 2022 | |
| Aimmune Therapeutics, INC. | $29.48 | 2024 | |
| Myriad Genetic Laboratories, INC. | $25.14 | 2024 | Myrisk |
| Incyte Corporation | $23.00 | 2025 | Zynyz |
| Tolmar, INC. | $21.97 | 2023 | |
| Progenics Pharmaceuticals, INC. | $16.92 | 2022 | |
| Nestle Healthcare Nutrition INC. | $15.30 | 2023 | |
| Abbvie INC. | $14.72 | 2022 | |
| Axonics, INC. | $13.75 | 2023 | Axonics |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mollie Deshazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.